Trial reportBMJ (Clinical research ed.)1992
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.
Trial report in BMJ (Clinical research ed.), 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 7 syntheses or guidelines pooled it, 434 citations in OpenAlex.
- [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].Wiener medizinische Wochenschrift. Supplement · 2009Guideline
- Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2005Guideline
- Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation.PharmacoEconomics · 2001Pooled it
- Guideline
- Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997Pooled it
- Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1996Guideline
- 2015 Guidelines for Osteoporosis in Saudi Arabia: Recommendations from the Saudi Osteoporosis Society.Annals of Saudi medicineGuideline
- Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2015Trial
- Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2006Trial
- Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.Rheumatology international · 2005Trial
- Trial
- Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997Trial
- Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1997Trial
- A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin.Calcified tissue international · 1996Trial
- Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis.Calcified tissue international · 1996Trial
- A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica.Calcified tissue international · 1996Trial
- Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1996Trial
- Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 1995Trial
- Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.Calcified tissue international · 1995Trial
- Trial
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study the dose related response of salmon calcitonin (salcatonin) given intranasally on bone mass and bone turnover and the effect of salcatonin on rates of fracture in elderly women with moderate osteoporosis.
designDouble blind, placebo controlled, randomised group comparison.
settingOutpatient clinic for research into osteoporosis. SUBJECTS: 208 healthy women aged 68-72 years who had a bone mineral content of the distal forearm on average 30% below the mean value for healthy premenopausal women.
interventionsThe 208 women were allocated randomly in blocks of four to two years of treatment with either salcatonin 50 IU, 100 IU, or 200 IU given intranasally or placebo. All groups received a calcium supplement of 500 mg. 32 of the women left the study before its end and 164 women complied with the study criteria throughout.
main outcome measuresBone mineral content of the distal forearm and lumbar spine and rates of vertebral and peripheral fractures after two years of treatment.
resultsThe average changes in bone mineral content of the spine showed positive outcomes of 1% (95% confidence interval -0.1% to 1.5%) in the group treated with calcium (placebo) and 3% (1.8% to 4.2%) in the group treated with salcatonin 200 IU. There was a significant dose related response to salcatonin, manifested by an increase of 1.0%/100 IU (0.2% to 1.7%, p = 0.008). The rate of patients with new fractures was reduced significantly in the women treated with salcatonin to about one third of that in the non-salcatonin treated women (relative risk 0.23 (0.07 to 0.77)).
conclusionThe results suggest that, compared with calcium alone, salcatonin given intranasally reduces the rates of fracture by two thirds in elderly women with moderate osteoporosis. Furthermore, it increases spinal bone mass in a dose dependent manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.